Meeting
2018 ASCO Annual Meeting
Phase 1b/2 study of olaratumab plus gemcitabine and docetaxel for the treatment of advanced soft tissue sarcoma (STS) (ANNOUNCE 2): Phase 1b results.
Authors
Victor Manuel Villalobos
University of Colorado, Denver, CO
Victor Manuel Villalobos , Andres Redondo , Brian Andrew Van Tine , Gary K. Schwartz , Mark Andrew Dickson , Bartosz Chmielowski , Patrick Peterson , Damien Cronier , Jennifer A. Wright , Steven Attia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT02659020
Citation
J Clin Oncol 36, 2018 (suppl; abstr 11542)
DOI
10.1200/JCO.2018.36.15_suppl.11542
Abstract #
11542
Poster Bd #
287
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase (Ph) 1b/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS).
First Author: Steven Attia
Poster
2023 ASCO Annual Meeting
A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
First Author: Lee D. Cranmer
Poster
2023 ASCO Annual Meeting
Results of SOC-2082 phase 2 study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab as second/third-line therapy for advanced sarcoma.
First Author: Nadezhda Omelchenko
Poster
2022 ASCO Annual Meeting
A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS).
First Author: Evan Rosenbaum